By Ben GlickmanShares of Co-Diagnostics rose on Wednesday after the company submitted an application to the Food and Drug Administration for its Covid-19 test platform. The Salt Lake City-based company said it had submitted its Co-Dx PCR Covid-19 test to the FDA for Emergency Use Authorization. The company's submission includes its PCR Pro instrument, the Covid-19 detection test and an associated mobile app. The company is also developing its Co-Dx platform to test for tuberculosis, HPV and certain other respiratory viruses. Write to Ben Glickman at ben.glickman@wsj.com(END) Dow Jones NewswiresDecember 27, 2023 12:52 ET (17:52 GMT)Copyright (c) 2023 Dow Jones & Company, Inc.

Source: Wall Street Journal December 27, 2023 19:43 UTC